Vycor Medical operates two separate medical device businesses. The first, Vycor Medical, designs and sells the ViewSite Brain Access System (VBAS), a minimally invasive retraction and access tool used in neurosurgery to reduce tissue disruption during brain and spine procedures. VBAS is FDA-cleared and CE-marked, and Vycor sells it directly to hospitals and neurosurgeons on a per-unit basis, primarily through its own distribution network. Revenue grows as more surgeons adopt VBAS and as the device is applied to a broader range of surgical indications. The second business, NovaVision, offers computer-based, non-invasive vision rehabilitation therapies — VRT and NeuroEyeCoach — targeting patients with neurological vision loss caused by stroke or brain injury. Patients use these therapies at home or in clinical settings. Rather than building a direct sales force for NovaVision, management is pursuing partnerships, licensing deals, or other third-party distribution arrangements to commercialize the platform. The company runs both divisions with a lean shared cost structure and only 7 employees, which limits its ability to independently scale either business. Growth priorities include expanding VBAS penetration domestically and internationally, broadening VBAS's clinical applicability, adding complementary products to the VBAS portfolio, and finding a partner, licensee, or buyer for NovaVision.